Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).

Ashish SharmaFrank G HolzCarl D RegilloK Bailey FreundDavid SarrafArshad M KhananiCaroline BaumalNancy M HolekampRamin TadayoniNilesh KumarNikulaa ParachuriBaruch D Kuppermann

Published in: Expert opinion on biological therapy (2023)

The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe. Members in training need more education related to biosimilars in the retina.

Keyphrases

diabetic retinopathy
primary care
optical coherence tomography
optic nerve
cross sectional
healthcare
health information
social media
drug induced
medical education